{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:57:22Z","timestamp":1784138242013,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rimegepant is a small\u2010molecule calcitonin gene\u2010related peptide receptor antagonist approved for the acute treatment of migraine\u00a0\u00b1\u00a0aura and preventive treatment of migraine in adults. The pharmacokinetics of rimegepant in elderly and nonelderly subjects were evaluated. In an open\u2010label Phase 1 study, 14 elderly (aged 65\u00a0years or older) and 14 nonelderly (aged 18 to less than 45 years) subjects each received a single oral dose of rimegepant 75\u00a0mg. Blood samples were collected before dosing and through 96 hours after dosing. The pharmacokinetic parameters of rimegepant after a single dose were similar in both age groups. Geometric least\u2010squares mean ratios (elderly\/nonelderly) of the natural log\u2010transformed maximum observed plasma concentration and natural log\u2010transformed area under the plasma concentration\u2013time curve from time 0 extrapolated to infinity were 96.6 and 104.6, respectively. Eight (28.6%) subjects (4 elderly, 4 nonelderly) experienced 1 or more adverse events (AEs); all AEs were mild in intensity, and no serious AEs or AEs leading to discontinuation were reported. Following a single 75\u2010mg dose of oral rimegepant, pharmacokinetic parameters were similar in elderly and nonelderly adults; no dose adjustment is warranted in elderly subjects.<\/jats:p>","DOI":"10.1002\/cpdd.1337","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:35:02Z","timestamp":1698734102000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75\u00a0mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open\u2010Label, Parallel\u2010Group, Single\u2010Dose Study"],"prefix":"10.1002","volume":"13","author":[{"given":"Rajinder","family":"Bhardwaj","sequence":"first","affiliation":[{"name":"Certara USA  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Morris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bertz","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2020.06.019"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_201"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1618830"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1895749"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00114-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2020.56.12.3211624"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221141686"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_2_9_22_1","first-page":"142","article-title":"A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant, a small molecule CGRP receptor antagonist","volume":"38","author":"Croop R","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1230"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231179131"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1244"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020954800"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1088"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00002"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357056163"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530902722679"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1140682"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328344533e"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2880"},{"key":"e_1_2_9_35_1","first-page":"26","article-title":"Sheehan Suicidality Tracking Scale (Sheehan\u2010STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder","volume":"6","author":"Coric V","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_2_9_36_1","first-page":"93","article-title":"Status update on the Sheehan\u2010Suicidality Tracking Scale (S\u2010STS) 2014","volume":"11","author":"Sheehan DV","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494758"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.04.005"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1546841"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14512"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010361741"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01577"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:41:35Z","timestamp":1705484495000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cpdd.1337"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1337","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"2023-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}